Press Release September 20, 2017

The Jackson Laboratory makes new AML mouse models available to researchers

Available with wide range of genetic mutations, growth profiles more closely mimicking the human population

Sacramento, Calif. – The Jackson Laboratory’s  In Vivo Pharmacology Our decades of mouse-based research experience in the fields of oncology, immunology and neurobiology, combined with unmatched knowledge of innovative murine mouse models of human disease, makes JAX a clear choice for advancing your research.In Vivo Pharmacology division is pleased to announce the launch of a collection of new human acute myeloid leukemia (AML) preclinical mouse models that more broadly represent AML subtypes seen in the human population. These early passaged tumor models, available and characterized in NSG™-SGM3 mice, were donated by David Weinstock’s lab at the Dana-Farber Cancer Institute to The Jackson Laboratory to improve the accessibility of AML models and propel scientific discoveries globally.

“The diversity represented by this panel allows researchers to better hone in on specific AML targets, creating an invaluable tool set to support drug discovery,” said David Weinstock, MD, Dana-Farber Cancer Institute.

“This is an important milestone in The Jackson Laboratory’s and Dana-Farber’s longstanding missions to improve accessibility of tumor models and support research and drug discovery,” said Dr. Walter Ausserer, associate general manager of In Vivo Services. “To that end, we have focused on making this panel highly accessible to the research community and can supply cohorts of these AML-bearing mice to scientists in both academic and industrial settings, in addition to executing drug efficacy studies at our Sacramento-based In Vivo pharmacology laboratory.”

Characterization data and information on accessing The Jackson Laboratory’s complete AML portfolio of models and services can be found at Patient Derived Acute Myeloid Leukemia (AML) Models and StudiesJAX offers ten AML patient-derived xenograft (PDX) models with varying mutational profiles and treatment histories. These models are available for analyzing the effectiveness of potential new drugs–alone or in combination–to treat AML.www.jax.org/aml .